📊 IBIO Key Takeaways
Is IBIO a Good Investment? Thesis Analysis
iBio is a pre-commercial stage pharmaceutical company with only $100K in annual revenue but $14.7M in operating losses, generating negative free cash flow of -$11.5M. While the company maintains a strong liquidity position ($28.7M cash, zero debt, 9.04x current ratio), at the current burn rate it has less than 2 years of runway before capital depletion, with no demonstrated path to profitability.
Why Buy IBIO? Key Strengths
- Exceptional liquidity with $28.7M in cash and 9.04x current ratio
- Zero debt burden provides operational flexibility and no interest obligations
- Reasonable equity base of $56.6M provides financial cushion for continued R&D
- Revenue growth of 77.8% YoY, though from negligible base
IBIO Investment Risks to Consider
- Unsustainable cash burn of $14.7M annually against zero meaningful revenue
- Negative operating cash flow of -$10.9M with runway of less than 24 months at current burn
- Gross profit anomaly ($2.2M on $100K revenue) suggests data quality or accounting irregularities
- Pre-commercial stage with no evidence of commercial traction or clear monetization path
- Highly speculative biotech venture dependent entirely on pipeline success with no near-term revenue visibility
Key Metrics to Watch
- Monthly cash burn rate and updated runway projections
- Path to clinical/regulatory milestones and commercialization timeline
- Gross margin normalization and revenue acceleration to validate business model
IBIO Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 9.04x current ratio provides a solid financial cushion.
IBIO Profitability Ratios
IBIO vs Healthcare Sector
How iBio, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is IBIO Overvalued or Undervalued?
Based on fundamental analysis, iBio, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
IBIO Balance Sheet & Liquidity
IBIO 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: iBio, Inc.'s revenue has grown significantly by 78% over the 5-year period, indicating strong business expansion. The most recent EPS of $-6.50 indicates the company is currently unprofitable.
IBIO Growth Metrics (YoY)
IBIO Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | N/A | -$4.0M | $-0.09 |
| Q1 2026 | N/A | -$4.0M | $-0.11 |
| Q3 2025 | N/A | -$3.2M | $-0.49 |
| Q2 2025 | $50.0K | -$4.0M | $-0.48 |
| Q1 2025 | N/A | -$4.0M | $-0.46 |
| Q3 2024 | N/A | N/A | $-0.85 |
| Q2 2024 | N/A | N/A | $-4.42 |
| Q1 2024 | N/A | N/A | $-0.24 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
IBIO Capital Allocation
IBIO SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for iBio, Inc. (CIK: 0001420720)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IBIO
What is the AI rating for IBIO?
iBio, Inc. (IBIO) has an AI rating of STRONG SELL with 88% confidence, based on fundamental analysis of SEC EDGAR filings.
What are IBIO's key strengths?
Claude: Exceptional liquidity with $28.7M in cash and 9.04x current ratio. Zero debt burden provides operational flexibility and no interest obligations.
What are the risks of investing in IBIO?
Claude: Unsustainable cash burn of $14.7M annually against zero meaningful revenue. Negative operating cash flow of -$10.9M with runway of less than 24 months at current burn.
What is IBIO's revenue and growth?
iBio, Inc. reported revenue of $100.0K.
Does IBIO pay dividends?
iBio, Inc. does not currently pay dividends.
Where can I find IBIO SEC filings?
Official SEC filings for iBio, Inc. (CIK: 0001420720) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IBIO's EPS?
iBio, Inc. has a diluted EPS of $-0.19.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is IBIO a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, iBio, Inc. has a STRONG SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is IBIO stock overvalued or undervalued?
Valuation metrics for IBIO: ROE of -26.0% (sector avg: 15%), net margin of -14,713.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy IBIO stock in 2026?
Our dual AI analysis gives iBio, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IBIO's free cash flow?
iBio, Inc.'s operating cash flow is $-10.9M, with capital expenditures of $548.0K. FCF margin is -11,454.0%.
How does IBIO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -14,713.0% (avg: 12%), ROE -26.0% (avg: 15%), current ratio 9.04 (avg: 2).